Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — JPM Conference 2026
27 slides from Daiichi Sankyo's conference presentation, Jan 12, 2026
Slide 1: The Top ADC Company: Becoming a Global Oncology Leader
The Top ADC Company Becoming a Global Oncology Leader DAIICHI SANKYO Hiroyuki Okuzawa President and CEO January 12, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda 1 Overview of Daiichi Sankyo 2 Our ADCs 3 Our Science and Technology 4 Shareholder Returns 5 Closing 3
Slide 4: Overview of Daiichi Sankyo
Overview of Daiichi Sankyo Overview of FY2025 consolidated P&L (Bn JPY) FY2025 Forecast as of Oct. 2025 to revenue vs FY2024 Revenue 2,100.0 100.0% ASCA +11.3% +213.7 *2 Cost of sales * 460.0 21.9% +44.3 SG&A expenses * 830.0 39.5% +105.2 R&D expenses * 460.0 21.9% Europe+27.1 Core operating profit
Slide 5: Agenda
Agenda 1 Overview of Daiichi Sankyo 2 Our ADCs 3 Our Science and Technology 4 Shareholder Returns 5 Closing 5
Slide 6: DXd ADC is Daiichi Sankyo Original ADC Technology Platform
DXd ADC is Daiichi Sankyo Original ADC Technology Platform Our ADC technology platform is growing, and we have generated 7DXd ADCs from the technology Asset Target tumor Pre-Clinical Ph1 Ph2 Ph3 Filed Launched (Target Antigen) ENHERTUⓇ BC, GC, NSCLC, (HER2) Solid Tumors DATROWAYⓇ BC, NSCLC, etc. (TR
Slide 7: External Evaluation of DXd ADC Technology
External Evaluation of DXd ADC Technology Since 2017, a total of 14 Breakthrough Therapy designations* have been granted in the United States Timing Indications Timing Indication August 2017 Third-line treatment for HER2-positive breast cancer EGFR-mutated non-small cell lung cancer with prior treat
Slide 8: Daiichi Sankyo Won Three World ADC Awards in 2025
Daiichi Sankyo Won Three World ADC Awards in 2025 Daiichi Sankyo’s DXd ADC Technology recognized for “Best ADC Platform Technology” TROP2 Directed ADC recognized for “Best ADC Clinical Impact” HER2 Directed ADC recognized for “Best ADC Clinical Publication” 8
Slide 9: ENHERTU global net sales by region since FY2019 launch
Daiichi Sankyo has delivered by maximizing ENHERTU® since our launch in FY2019 and created the most successful launch in oncology over the last 5 years ENHERTU® GLOBAL NET SALES BY REGION (Bn JPY) 155.2 163.2 1573.4 Bn JPY cumulative global net sales since 1st launch 148.4 143.1 129.6 131.7 119.9 Gl
Slide 10: DESTINY-Breast09: ENHERTU 1st Line HER2+ mBC launch as growth catalyst
DESTINY-Breast09: Launch of ENHERTU® in 1st Line HER2+ mBC will be a near-term growth catalyst with potential to benefit 24k eligible patients Market Opportunity DESTINY-Breast09 Clinical trial data: PFS (BICR) (Eligible patient numbers) ~24,000* • Currently, ~30% of patients do not receive treatmen
Slide 11: Global DATROWAY net sales exceeded 10 Bn JPY in Q2 FY25
Global DATROWAY® net sales have now exceeded 10 Bn JPY in Q2 FY ‘25 DATROWAY® GLOBAL NET SALES BY REGION (Bn JPY) 10.4 17.1 Bn JPY cumulative global net sales since 1st launch Overall, global net sales in FY2025 Q2 was 10.4 Bn JPY; +95.9% sequential QtQ growth driven by US and Japan 5.3 1.4 FQ4'24 F
Slide 12: TROPION-Breast02 showed significant PFS and OS improvement
TROPION-Breast02 study showed a statistically significant & clinically meaningful improvement in PFS and OS compared with ICC TROPION-Breast02 Clinical trial data Market Opportunity (Eligible patient numbers) TB02: ~16,000 Dato-DXd ICC Δ Median PFS 10.8 mo 5.6 mo Δ 5.3 mo Market opportunity in G7 Me
Slide 13: Plans to launch numerous indications across at least 4 ADCs by 2030
Daiichi Sankyo plans to launch numerous indications across at least 4 ADCs by 2030, contributing nearly six times as many patients *Arrow size is Illustrative ~700k Eligible Others Patients US Merck DATROWAY ® Alliance Growth • IDeate-Lung01 • IDeate-Lung02 • AVANZAR • IDeate-Esophageal01 • TROPION
Slide 14: Our Proprietary Technologies X ADC-leading Expertise
The Evolution of Our ADC Technologies Will Continue 15 years of ADC platform advancement - expanding Innovation Antibody Linker Payload ✓ Unique binders targeting disease specific ✓ DAR control ✓ FIC/BIC Cytotoxic payloads proteins and glycans ✓ Site specificity • DXd, mPBD, etc. ✓ Fc engineering ✓
Slide 15: Sustainable ADC Platform Development
Sustainable ADC Platform Development 5 4 3 1 2 DXd ADC mPBD ADC STING New Concept New Concept New New Concept Concept agonist ADC ADC 1 ADC 2 ADC ADC 3 4 ENHERTU® DS-9606 DATROWAY® DS3610 Multiple projects Multiple projects • •・ Expanding into in discovery stage in discovery stage I-DXd Multiple pro
Slide 16: Agenda
Agenda 1 Overview of Daiichi Sankyo 2 Our ADCs 3 Our Science and Technology 4 Shareholder Returns 5 Closing 16
Slide 17: Why We Invest in IO?
Why We Invest in IO? Immuno-Oncology (IO) Franchise Unlocking durable benefit, expanding treatment options, and maximizing internal asset value. Durable Effect Immune Memory IO therapies can deliver long-lasting remission Activated immune cells ‘remember’ tumor antigens beyond the treatment period.
Slide 18: Our 10 Years Research History Has Built the IO Franchise
Our 10 Years Research History Has Built the IO Franchise Leveraging a multi-modality strategy, we are establishing a portfolio that targets and activates key mechanisms in IO signaling ■New modality (ADC, TCE) APC activation Treg inhibition ■Antibody • DS-1103 (Ph1) Anti-CCR8 Ab • DS3610 (Ph1) ■Smal
Slide 19: Daiichi Sankyo Takes Multi-Modality Strategy
Daiichi Sankyo Takes Multi-Modality Strategy Establishing proprietary technologies unique to Daiichi Sankyo and building a robust and competitive drug discovery platform across diverse modalities. ADC Platform New Modalities (beyond ADC) DXd ADC mPBD ADC Multispecific Mid-size Molecule Nucleotide An
Slide 20: Global In-House Manufacturing Sites
Global In-House Manufacturing Sites Altkirch, France Pfaffenhofen, Germany Shanghai, China Onahama Shirley, NY DS DP mAb DP DS Brea, CA Tatebayashi mAb New Albany, Ohio Kitamoto DP Building an ADC supply structure Hilliard, Ohio through seven in-house sites and multiple CMOs Hiratsuka DS DP Alphavil
Slide 21: Agenda
Agenda 1 Overview of Daiichi Sankyo 2 Our ADCs 3 Our Science and Technology 4 Shareholder Returns 5 Closing 21
Slide 22: Shareholder Return Policy (FY2021-FY2025)
Shareholder Return Policy (FY2021-FY2025) Capital efficiency improvement Shareholder returns enhancement ➢ Profit growth driven by 3ADCs ➢ Dividend increase taking account of ➢ Flexible acquisition of own shares profit growth ➢ Flexible acquisition of own shares FY2025 Target: ROE > 16% ➢ Stable sha
Slide 23: FY2025 Annual Dividend Forecast
FY2025 Annual Dividend Forecast Plan to increase annual dividend to 78 JPY per share for FY2025 (up 18 JPY) due to strong performance of ENHERTU® and others 331.9 Bn JPY 335.0 Bn JPY 78 JPY Annual Dividend per share Year-end Dividend 211.6 Bn JPY 60 JPY Interim Dividend 39 Operating Profit 50 JPY 30
Slide 24: Agenda
Agenda 1 Overview of Daiichi Sankyo 2 Our ADCs 3 Our Science and Technology 4 Shareholder Returns 5 Closing 24
Slide 25: Highly confident to reach top 10 oncology company goal
Daiichi Sankyo remains highly confident we will reach and exceed our goal to be a top 10 oncology company GLOBAL ONCOLOGY PRODUCT SALES ($B) 35 30 25 20 15 10 5 0 Source: Evaluate Pharma, accessed November 19, 2025 *MAT = Moving Annual Total (MAT Sept 2025 refers to Oct 2024 – Sept 2025 period B: bi
Slide 26: Contributing to the enrichment of quality of life around the world
Daiichi Sankyo will contribute to the enrichment of quality of life around the world 26
Slide 27: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1125 Email: DaiichiSankyoIR_jp@daiichisankyo.com 27